Park, Jung-eun Song, Chiman Choi, Keehyun Sim, Taebo Moon, Bongjin Roh, Eun Joo 2024-01-20T11:30:18Z 2024-01-20T11:30:18Z 2021-09-05 2013-10-15 0960-894X https://pubs.kist.re.kr/handle/201004/127545 A series of 3,4-diarylpyrrolidin-2-one was designed, prepared and evaluated as triple reuptake inhibitors for antidepressant. Most compounds exhibited comparable in vitro efficacy as norepinephrine and dopamine transporter reuptake inhibitors. Especially, 2i showed better potency than GBR-12909 (IC50 = 14 - nM) which was used as reference compound for dopamine transporter. In addition, 2a and 2b showed inhibition (5.17 mu M-85.6 nM) for three transporters. (C) 2013 Elsevier Ltd. All rights reserved. English Pergamon Press Ltd. PHARMACOLOGICAL EVALUATION MAJOR DEPRESSION PROFILE POTENT AGENTS Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors Article 10.1016/j.bmcl.2013.08.062 1 Bioorganic & Medicinal Chemistry Letters, v.23, no.20, pp.5515 - 5518 Bioorganic & Medicinal Chemistry Letters 23 20 5515 5518 scie scopus 000324304000008 2-s2.0-84884282193 Chemistry, Medicinal Chemistry, Organic Pharmacology & Pharmacy Chemistry Article PHARMACOLOGICAL EVALUATION MAJOR DEPRESSION PROFILE POTENT AGENTS Triple reuptake inhibitors Monoamine Reuptake Depression Antidepressant Serotonin Dopamine Norepinephrine Lactam